Dr. Stephan Rau focuses his practice on mergers and acquisitions (M&A) transactions and regulatory advice in the health and life science sector. He is the head of the Firm’s Health Law Practice Group in Europe.
In 2004, Stephan was adviser on the foundation of the first German corporate medical center. Since then he has represented numerous investors, health care service providers, pharmaceutical and medtech companies, as well as governmental entities in M&A transactions, outsourcing projects, and licensing and reimbursement proceedings.
Stephan speaks regularly at health care and life sciences industry as well as legal expert conferences, both at an international and national level. He is the author of numerous publications on German corporate law, health care and life sciences regulation.
For many years Stephan has consistently been ranked Tier 1 attorney for Health in Germany by Chambers Europe and “Elite Leading Lawyer” for Health and Life Sciences by Legal 500 Germany. JUVE lists Stephan as a frequently recommended lawyer for Corporate, M&A and Private Equity and a leading advisor for health. LMG Life Sciences Europe has repeatedly listed Stephan as a “Life Sciences Star” for his outstanding work in the industry.
Education
Humboldt University of Berlin, Dr. jur. (PhD), 2003
Higher Court of Appeal, Berlin, Second State Exam, 1998
University of Heidelberg, First State Exam, 1996
University of Paris-Dauphine, Maîtrise en Économie Appliquée, 1994
London School of Economics and Political Science, Master of Science in Government, 1993
IHK Wiesbaden, interpreter and translator for Russian, 1990
Admissions
Germany
Courts / Agencies
All Courts and Courts of Appeal in Germany
Languages
English
German
French
Russian
Socio | Monaco
Munich: +49 89 12712 322
Munich: +49 89 12712 117
Shanghai, China / McDermott Event / November 12, 2019
London, United Kingdom / McDermott Event / September 26, 2019
On the Subject / April 2019
Berlin, Germany / McDermott Event / February 27, 2019
London, United Kingdom / McDermott Event / October 4, 2018
Munich, Germany / McDermott Event / September 25, 2018
Copenhagen, Denmark / McDermott Event / June 13, 2018
Copenhagen, Denmark / Speaking Engagements / June 12, 2018
Copenhagen, Denmark / Speaking Engagements / June 11, 2018
Shanghai, China / McDermott Event / November 16, 2017
Munich, Germany / McDermott Event / September 19, 2017
London, United Kingdom / McDermott Event / June 28, 2017
San Francisco, California / McDermott Event / January 10, 2017
On the Subject / November 21, 2016
On the Subject / June 28, 2016
UnternehmerEdition "Health“, Issue 4 / October 2015
Telemedicine in Germany - What Legal Changes Are Needed and What Are ...
PharmaRecht, Issue 4 / April 30, 2015
Comparable Drugs in Price Negotiations Under Sec. 130b SGB V
Pharmind, Issue 11 / November 2014
New Developments On Combating Corruption and Compliance In Healthcare
International Law Office Newsletter, Germany / October 29, 2014
German Perspective on New EU Clinical Trials Regulation
Tokyo, Japan / Diversity Event / October 22, 2014
On the Subject / October 20, 2014
Munich, Germany / Diversity Event / September 24, 2014
International Law Office Newsletter, Germany / June 18, 2014
Pricing for New Innovative Drugs – Public Payers Attempt New Approach
VC Magazine / April 23, 2014
Legal Framework for Health Apps
International Law Office Newsletter, Germany / February 26, 2014
Generic Drug and API Producers Deal with the Bolar Exemption
International Law Office Newsletter, Germany / February 19, 2014
Yet another Health Reform and Seizure of Retiring Doctors' Practices
Healthcare Marketing - Das Fachmagazin für Gesundheitsmarken, Issue 1-2 / January 2014
Patent Expirations: Generic Drugs and Active Ingredient Producers from the Perspective of ...
1
2
3
4
5
Global Legal Chronicle / November 19, 2019
United Homecare Partners’ Acquisition of German and Austrian Nursing Healthcare at Home ...
RWS Verlag / November 4, 2019
McDermott Advises Healthcare at Home on the Sale of German and Austrian ...
Healthcare Business International / October 31, 2019
London / Press Releases / September 18, 2019
McDermott to Host European Healthcare Private Equity Leadership Forum 2019
London / Accolades & Rankings / April 15, 2019
London / Accolades & Rankings / March 18, 2019
Düsseldorf / Press Releases / December 4, 2018
McDermott Continues to Showcase Innovative Client Service and Strategic Growth as Top 25 ...
Monaco / The Lawyer / October 3, 2017
Monaco / Global Legal Chronicle / July 31, 2017
Eurofins Scientific SE’s Acquisition of MVZ für Laboratoriumsmedizin of Hygel
Bruxelles / Press Releases / June 30, 2017
Düsseldorf / Press Releases / May 8, 2017
Düsseldorf / Accolades & Rankings / April 18, 2017
McDermott Recommended in Legal 500 EMEA 2017 and Top-Tier Ranked in France for Healthcare ...
Düsseldorf / Accolades & Rankings / April 10, 2017
Düsseldorf / Press Releases / January 6, 2017
McDermott Maintains Strong Rankings in The Legal 500 Deutschland 2017
Monaco / Juve (Germany) / September 25, 2016
In-Pharma Technologist / August 1, 2016
AstraZeneca: Retaining Current Regulatory Procedures Crucial, Post-Brexit
London / In-Pharma Technologist / July 27, 2016
GSK Commits to UK Manufacturing with £275m Investments Across Three Sites
Pharmaceutical Processing / July 22, 2016
The Events Leading to the Brexit & What It Means for Pharma’s ...
London / Drug Discovery News / July 2016
IBA [International Bar Association] Global Insight / April 12, 2016
JUVE (Germany) / June 29, 2015
Laboratory Services: Cinven Works with Clifford to Buy Synlab for 1.2 Billion Euros
Düsseldorf / Accolades & Rankings / May 5, 2015
McDermott European Practice Shows Continuous Growth in Ranking Results in Chambers Europe 2015
1
2
3
4
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.
We use cookies to improve the functionality and performance of this site. By continuing to use this site, you are providing us with your consent to our use of cookies. Please see our Privacy Policy for details.
